86 related articles for article (PubMed ID: 17616632)
1. Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.
Jobson AG; Cardellina JH; Scudiero D; Kondapaka S; Zhang H; Kim H; Shoemaker R; Pommier Y
Mol Pharmacol; 2007 Oct; 72(4):876-84. PubMed ID: 17616632
[TBL] [Abstract][Full Text] [Related]
2. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].
Jobson AG; Lountos GT; Lorenzi PL; Llamas J; Connelly J; Cerna D; Tropea JE; Onda A; Zoppoli G; Kondapaka S; Zhang G; Caplen NJ; Cardellina JH; Yoo SS; Monks A; Self C; Waugh DS; Shoemaker RH; Pommier Y
J Pharmacol Exp Ther; 2009 Dec; 331(3):816-26. PubMed ID: 19741151
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.
Lountos GT; Tropea JE; Zhang D; Jobson AG; Pommier Y; Shoemaker RH; Waugh DS
Protein Sci; 2009 Jan; 18(1):92-100. PubMed ID: 19177354
[TBL] [Abstract][Full Text] [Related]
4. Targeting chk2 kinase: molecular interaction maps and therapeutic rationale.
Pommier Y; Sordet O; Rao VA; Zhang H; Kohn KW
Curr Pharm Des; 2005; 11(22):2855-72. PubMed ID: 16101442
[TBL] [Abstract][Full Text] [Related]
5. Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors.
Nguyen TN; Saleem RS; Luderer MJ; Hovde S; Henry RW; Tepe JJ
ACS Chem Biol; 2012 Jan; 7(1):172-84. PubMed ID: 22004065
[TBL] [Abstract][Full Text] [Related]
6. Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage.
Bahassi el M; Myer DL; McKenney RJ; Hennigan RF; Stambrook PJ
Mutat Res; 2006 Apr; 596(1-2):166-76. PubMed ID: 16481012
[TBL] [Abstract][Full Text] [Related]
7. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis.
Powers JT; Hong S; Mayhew CN; Rogers PM; Knudsen ES; Johnson DG
Mol Cancer Res; 2004 Apr; 2(4):203-14. PubMed ID: 15140942
[TBL] [Abstract][Full Text] [Related]
8. Protein phosphatase 2A interacts with Chk2 and regulates phosphorylation at Thr-68 after cisplatin treatment of human ovarian cancer cells.
Liang X; Reed E; Yu JJ
Int J Mol Med; 2006 May; 17(5):703-8. PubMed ID: 16596250
[TBL] [Abstract][Full Text] [Related]
9. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe.
Castedo M; Perfettini JL; Roumier T; Yakushijin K; Horne D; Medema R; Kroemer G
Oncogene; 2004 May; 23(25):4353-61. PubMed ID: 15048074
[TBL] [Abstract][Full Text] [Related]
10. Chk2 molecular interaction map and rationale for Chk2 inhibitors.
Pommier Y; Weinstein JN; Aladjem MI; Kohn KW
Clin Cancer Res; 2006 May; 12(9):2657-61. PubMed ID: 16675556
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles.
Arienti KL; Brunmark A; Axe FU; McClure K; Lee A; Blevitt J; Neff DK; Huang L; Crawford S; Pandit CR; Karlsson L; Breitenbucher JG
J Med Chem; 2005 Mar; 48(6):1873-85. PubMed ID: 15771432
[TBL] [Abstract][Full Text] [Related]
12. Development of a fluorescence polarization bead-based coupled assay to target different activity/conformation states of a protein kinase.
Lu Z; Yin Z; James L; Syto R; Stafford JM; Koseoglu S; Mayhood T; Myers J; Windsor W; Kirschmeier P; Samatar AA; Malcolm B; Turek-Etienne TC; Kumar CC
J Biomol Screen; 2004 Jun; 9(4):309-21. PubMed ID: 15191648
[TBL] [Abstract][Full Text] [Related]
13. Ataxia telangiectasia mutated and checkpoint kinase 2 regulate BRCA1 to promote the fidelity of DNA end-joining.
Wang HC; Chou WC; Shieh SY; Shen CY
Cancer Res; 2006 Feb; 66(3):1391-400. PubMed ID: 16452194
[TBL] [Abstract][Full Text] [Related]
14. Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.
Lountos GT; Jobson AG; Tropea JE; Self CR; Zhang G; Pommier Y; Shoemaker RH; Waugh DS
J Struct Biol; 2011 Dec; 176(3):292-301. PubMed ID: 21963792
[TBL] [Abstract][Full Text] [Related]
15. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.
Anderson VE; Walton MI; Eve PD; Boxall KJ; Antoni L; Caldwell JJ; Aherne W; Pearl LH; Oliver AW; Collins I; Garrett MD
Cancer Res; 2011 Jan; 71(2):463-72. PubMed ID: 21239475
[TBL] [Abstract][Full Text] [Related]
16. Role of CHK2 in cancer development.
Perona R; Moncho-Amor V; Machado-Pinilla R; Belda-Iniesta C; Sánchez Pérez I
Clin Transl Oncol; 2008 Sep; 10(9):538-42. PubMed ID: 18796370
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
Hilton S; Naud S; Caldwell JJ; Boxall K; Burns S; Anderson VE; Antoni L; Allen CE; Pearl LH; Oliver AW; Wynne Aherne G; Garrett MD; Collins I
Bioorg Med Chem; 2010 Jan; 18(2):707-18. PubMed ID: 20022510
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability.
Stolz A; Ertych N; Bastians H
Clin Cancer Res; 2011 Feb; 17(3):401-5. PubMed ID: 21088254
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation.
Schwarz JK; Lovly CM; Piwnica-Worms H
Mol Cancer Res; 2003 Jun; 1(8):598-609. PubMed ID: 12805407
[TBL] [Abstract][Full Text] [Related]
20. Autophosphorylated residues involved in the regulation of human chk2 in vitro.
Gabant G; Lorphelin A; Nozerand N; Marchetti C; Bellanger L; Dedieu A; Quéméneur E; Alpha-Bazin B
J Mol Biol; 2008 Jul; 380(3):489-503. PubMed ID: 18538787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
